Gordon Johnson - KemPharm Chief Bus. Officer

KMPHDelisted Stock  USD 5.81  0.02  0.34%   

Executive

Mr. Gordon K. Johnson is Chief Business Officer of the Company. Previously, Mr. Johnson served as our chief operating officer and chief financial officer from July 2013 to June 2015. Prior to joining our company, Mr. Johnson was the president and chief operating officer of Citius Pharmaceuticals, LLC, a specialty pharmaceutical company, from November 2012 to July 2013. From July 2012 to October 2012, Mr. Johnson was the executive vice president and chief business officer of Direct Markets, Inc., a technology company. From June 2011 to July 2012, Mr. Johnson served as a managing director of Rodman Renshaw, LLC. Prior to that, he was a managing director at Piper Jaffray Co. from 2007 to March 2011 since 2015.
Age 66
Tenure 9 years
Professional MarksMBA
Phone321 939 3416
Webhttps://kempharm.com
Johnson received his M.B.A. degree from Harvard Business School and his B.A. degree from the University of Missouri.

KemPharm Management Efficiency

The company has return on total asset (ROA) of (0.0897) % which means that it has lost $0.0897 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3124) %, meaning that it created substantial loss on money invested by shareholders. KemPharm's management efficiency ratios could be used to measure how well KemPharm manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 16.16 M in liabilities with Debt to Equity (D/E) ratio of 0.16, which may suggest the company is not taking enough advantage from borrowing. KemPharm has a current ratio of 11.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist KemPharm until it has trouble settling it off, either with new capital or with free cash flow. So, KemPharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like KemPharm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for KemPharm to invest in growth at high rates of return. When we think about KemPharm's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Scott DavisWestern Digital
N/A
Chirantan DesaiServiceNow
53
Moran AdaniaRadcom
N/A
David TangWestern Digital
59
Tiang TanWestern Digital
54
Robert MorganIdaho Strategic Resources
56
Lori SundbergWestern Digital
51
Pat WadorsServiceNow
52
Stephen BodleyGatos Silver
57
Gregory BryantAnalog Devices
55
Patrick ODohertyAnalog Devices
N/A
John EtienneIdaho Strategic Resources
N/A
Anthony BencivengaArrow Electronics
N/A
Gretchen ZechArrow Electronics
54
Patricia WadorsServiceNow
54
Michael SondelAnalog Devices
47
Anelise SacksAnalog Devices
45
Percy PascalGatos Silver
N/A
Daniel LeibholzAnalog Devices
N/A
CPA PhillipNextplat Corp
65
Guy ShemeshRadcom
N/A
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. KemPharm (KMPH) is traded on NASDAQ Exchange in USA and employs 24 people.

Management Performance

KemPharm Leadership Team

Elected by the shareholders, the KemPharm's board of directors comprises two types of representatives: KemPharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of KemPharm. The board's role is to monitor KemPharm's management team and ensure that shareholders' interests are well served. KemPharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, KemPharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christal MA, CoFounder Devel
Joseph Saluri, Independent Director
LaDuane CPA, S CFO
Timothy Sangiovanni, Principal Accounting Officer, Vice President Corporate Controller
Gordon Johnson, Chief Bus. Officer
Nichol Ochsner, VP Communications
Danny Thompson, Independent Director
David Tierney, Independent Director
Timothy CPA, VP Controller
Sven Guenther, Executive Vice President -Research and Development
LaDuane Clifton, CFO
Andrew Barrett, VP Affairs
Travis Mickle, Founder, Chairman, CEO and President and Member of Scientific and Medical Advisory Board
Matthew Plooster, Independent Director
Richard Pascoe, Lead Independent Director

KemPharm Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is KemPharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in KemPharm Stock

If you are still planning to invest in KemPharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the KemPharm's history and understand the potential risks before investing.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.